Table 1.
List of clinical trials which are single use of promising candidates.
| Single Use Candidate Vaccines | Current Status | Sponser | Start Date | Phase | Estimated Enrollments | Ages | Locations | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|---|---|---|
| Ad5-EBOV | Completed | NIAID | Sept.2010 | 1 | 48 | 18-50 | USA | NCT00374309 |
| Ad5-EBOV | Completed | JSCDC | Dec.2014 | 1 | 120 | 18-60 | China | NCT02326194 |
| Completed | JSCDC | Jul.2015 | 1 | 110 | 18-60 | China | NCT02533791 | |
| Completed | FAHZU | May.2015 | 1 | 61 | 18-60 | China | NCT02401373 | |
| Ongoing | JSCDC | Oct.2015 | 2 | 500 | 18-50 | Sierra Leone | NCT02575456 | |
| DNA | Completed | NIAID | Oct.2003 | 1 | 27 | 18-44 | USA | NCT00072605 |
| Completed | NIAID | Jan.2008 | 1 | 20 | 18-60 | USA | NCT00605514 | |
| Completed | NIAID | Fre.2010 | 1 | 108 | 18-50 | Uganda | NCT00997607 | |
| rVSV-EBOV | Completed | Merck Sharp & Dohme Corp | Oct.2014 | 1 | 120 | 18-65 | USA | NCT02280408 |
| Completed | Merck Sharp & Dohme Corp | Oct.2014 | 1 | 39 | 18-50 | USA | NCT02269423 | |
| Completed | Dalhousie University | Nov.2014 | 1 | 40 | 18-65 | Not Provided | NCT02374385 | |
| Completed | UHE | Nov.2014 | 1 | 30 | 18-65 | Germany | NCT02283099 | |
| Completed | Merck Sharp & Dohme Corp | Dec.2014 | 1 | 512 | 18-60 | USA | NCT02314923 | |
| Completed | University Hospital, Geneva | Dec.2014 | 1 & 2 | 115 | 18-65 | Switzerland | NCT02287480 | |
| Ongoing | University of Oxford | Dec.2014 | 1 | 40 | 18-55 | Kenya | NCT02296983 | |
| Ongoing | Novavax | Feb.2015 | 1 | 230 | 18-50 | Australia | NCT02370589 | |
| Ongoing | CDC | Apr.2015 | 2 & 3 | 8000 | 18+ | Sierra Leone | NCT02378753 | |
| Ongoing | Merck Sharp & Dohme Corp | Aug.2015 | 3 | 1198 | 18-65 | USA, Canada, Spain | NCT02503202 | |
| Ongoing | Profectus BioSciences, Inc. | Jan.2016 | 1 | 38 | 18-60 | USA | NCT02718469 | |
| Not recruit | NIAID | Jan.2016 | 2 | 300 | 18+ | USA | NCT02788227 | |
| cAd3-EBO | Completed | CHUV | Oct.2014 | 1 & 2 | 120 | 18-65 | Switzerland | NCT02289027 |
| Ongoing | GSK | Jul.2015 | 2 | 2796 | 18+ | Senegal | NCT02485301 | |
| cAd3-EBO/ChAd3-EBO-Z | Ongoing | NIAID | Aug.2014 | 1 | 50 | 18-65 | USA | NCT02231866 |
| HPIV3-EBO-Z | Ongoing | NIAID | Aug.2015 | 1 | 30 | 18-50 | USA | NCT02564575 |
Abbreviations: NIAID = National Institute of Allergy and Infectious Diseases; JSCDC = Jiangsu Province Centers for Disease Control and Prevention FAHZU = First Affiliated Hospital of Zhejiang University; NLGC = NewLink Genetics Corporation; UHE = Universitätsklinikum Hamburg-Eppendorf; CDC = Centers for Disease Control and Prevention; CHUV = Center Hospitalier Universitaire Vaudois; GSK = GlaxoSmithKline; USA = United States.